


**Remarks**

Claims 1-119 are pending in the application. Applicant respectfully traverses Examiner's restriction requirement in part. In compliance with the restriction request, Applicant elects the Group I claims with traverse. Applicant provisionally elects the following specie having the following structure



and chemical name, 1-[7-(2-Chloro-phenyl)-8-(4-chloro-phenyl)-2-methyl-pyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-ethylamino-azetidine-3-carboxylic acid amide, as the elected specie upon which the Examiner can initiate the examination of the elected claims. The provisionally elected specie falls within the scope of all pending claims as amended by this amendment. The specie is specifically claimed in Claims 19 and 20, and new Claims 120 and 121.

Applicant would like to point out that some of the Group VI claims may be rejoined in accordance with the provisions of MPEP §821.04. Examiner's Group VI claims contain a mixture of different types of claims including (i) compositions comprising a combination of active ingredients including compounds of the present invention, (ii) methods of use for the compounds of the present invention or a pharmaceutical composition thereof, and (iii) methods of use for combinations with the compounds of the present invention.

In response to part of the Group VI restriction requirement, Applicants have cancelled the subject matter directed to the pharmaceutical compositions comprising a combination of active ingredients (Claims 98-100) and methods of using a combination of active ingredients (Claims 103-105, 109-111, and 113-117), without waiver or prejudice and without admission of anticipation or obviousness. Applicants reserve the right to file divisional applications to capture the cancelled restricted subject matter.

However, Applicants respectfully disagree with Examiner's restriction with respect to Claims 101, 106, 107, 108 and 112. Claim 101 and dependent Claims 106 and 107 are

directly linked to the compounds of Claim 1. Similarly, the method Claim 108 and dependent Claim 112 are directly linked to the composition Claim 97. Claims 101 and 108 have been amended to include all the limitations of the Group I compound and pharmaceutical composition claims, Claims 1 and 97, respectively; therefore, there would be no added burden on the Examiner to consider the pending method of use claims along with the compounds of Claim 1. Even though the method of use claims may be independent and distinct, these claims would be subject to rejoinder when the compounds of Claim 1 are found allowable. (see, MPEP 821.04).

Claim 1 has been amended to correspond to the restriction requirement by removing the non-elected groups where R<sup>4</sup> is a group of Formula IB, Formula IC and an amino group (iii).

Claims 37-55, 81-96, 98-100, 103-105, 109-111 and 113-119 have been cancelled as being directed to non-elected subject matter.

Claim 57 has been cancelled since it would not further limit the amended Claim 56 from which it depends. Similarly, Claim 102 was cancelled since it would not further limit the amended withdrawn Claim 101 from which it depends.

Claim 58 has been amended to provide proper dependency.

Withdrawn Claims 106 and 112 have been amended to provide proper dependency and to limit the claims to the elected subject matter corresponding to the Group I claims.

Support for new Claims 120 and 121 may be found in Example 2 (Compound No. 2A-1 and corresponding salts) of the specification on pages 101-104.

Respectfully Submitted:

Date: September 2, 2005

Arlene K. Musser  
Arlene K. Musser  
Attorney for Applicants  
Registration No. 37,895

Pfizer Inc.  
Patent Department, Box 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 715-0871